Business, energy, technology, markets and global industry news from Business News Today

Shanghai Henlius Biotech

PharmaDeviceNews Shanghai Henlius Biotech
Genentech’s Gazyva enters FDA Priority Review for primary membranous nephropathy following the Phase III MAJESTY remission results. Representative image.
Pharma & Biotech

Palleon Pharmaceuticals reports rapid remissions with HLX79/E-602 in Phase 2 kidney disease trial

Palleon's HLX79/E-602 achieved remission in all seven high-dose patients by Week 36. Can the small Phase 2 kidney trial support larger studies?

Read More
Representative image: Roche sefaxersen hits Phase III IgA nephropathy endpoint as once-monthly therapy moves closer to regulatory review.
Pharma & Biotech

Palleon to present HLX79 and rituximab combination data at ACR Convergence 2026

Palleon Pharmaceuticals will present interim Phase 2 results for HLX79 plus a rituximab biosimilar in membranous nephropathy. A publicly available abstract reports 17 remissions among 26 patients, although the blinded analysis includes patients receiving rituximab without HLX79.

Read More
Sandoz has secured ex-China commercialization rights to an initial biosimilar portfolio under a collaboration worth up to $322 million, while Henlius retains responsibility for development, manufacturing and supply. Representative image.
Pharma & Biotech

Sandoz-Henlius $322m biosimilar deal starts with three blockbusters and could expand to 10 assets

Sandoz gains ex-China commercialization rights to an initial biosimilar portfolio while Henlius retains development, manufacturing and supply responsibilities under a collaboration worth up to $322 million.

Read More
Pharma & Biotech

Palleon Pharmaceuticals tests B7-H3-targeted sialidase in ovarian cancer, what changes now?

Palleon Pharmaceuticals has moved E-688/HLX316 into human testing. Read why this B7-H3 sialidase could reshape immuno-oncology.

Read More